Matthew Spindler

Matthew Spindler has a diverse work experience in the field of biomedical research. Matthew worked as the VP for Research at GigaMune starting from September 2018. Prior to that, they worked at GigaGen Inc from 2014, holding roles such as Director of Cell Engineering and Strategic Alliances Manager. Their responsibilities at GigaGen Inc included using advanced single cell microfluidics and molecular biology techniques for sequencing and expression analysis of human T cell receptor repertoires. Matthew also led immuno-oncology projects and academic collaborations to expand the company's technology platform.

Before joining GigaGen Inc, Matthew was a Postdoctoral Fellow at Stanford University School of Medicine, where they worked with the Human Immune Monitoring Center on the development of a microfluidics-based, single cell sequencing system for T cell repertoire analysis. Matthew also conducted single cell FACS sorting and downstream analysis of T cells from patient samples.

Prior to that, Matthew worked as a Postdoctoral Fellow at The Gladstone Institutes, where they led a team in optimizing cardiomyocyte differentiation protocols using human stem cells. Their research focused on understanding cardiovascular development and disease. Matthew also investigated methods to enhance ventricular differentiation and maturation.

Matthew started their research career as a Graduate Student at UCSF, where they completed their Ph.D. thesis on identifying the role of the signaling scaffold AKAP13 during cardiovascular development and disease. Matthew generated mutant mouse lines to study the importance of AKAP13 protein domains in mouse development and drug-induced cardiac hypertrophy.

Overall, Matthew Spindler's work experience highlights their expertise in single cell sequencing, molecular biology, immuno-oncology, stem cell research, and cardiovascular development.

Matthew Spindler earned their Bachelor of Science (B.S.) degree in Genetics from the University of Wisconsin-Madison, where they studied from 1999 to 2003. Later, they pursued a Doctor of Philosophy (Ph.D.) in Pharmaceutical Sciences and Pharmacogenomics from the University of California, San Francisco, from 2003 to 2011.